- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Study: Combination of Ultrasound and MRI-Targeted Biopsy Enhances Detection of Prostate Cancer
In a study of 413 men with suspected prostate cancer, researchers found the combination of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy diagnosed prostate cancer in 72.9 percent of patients in comparison to 60.2 percent with systematic biopsy alone.
Emerging research suggests that employing ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy may offer better detection of prostate cancer than systematic biopsy alone.
For the prospective, randomized multicenter study, published recently in Radiology, researchers assessed the use of multiparametric magnetic resonance imaging (MRI) in 582 men (mean age of 65) with suspected prostate cancer (PCa). The study authors also compared the combination of ultrasound and MRI fusion-targeted biopsies with systematic biopsy versus systematic biopsy alone for diagnostic accuracy in prostate cancer imaging.
For 89 men who had positive MRI findings and had a laparoscopic radical prostatectomy, the researchers found that multiparametric MRI successfully identified 131 out of 182 foci with clinically significant prostate cancer (csPCa). In addition to a sensitivity rate of 72 percent, multiparametric MRI had a 71 percent specificity rate and a positive predictive value (PPV) of 78 percent, according to the study. The researchers pointed out that MRI diagnosed 87 percent of cancers with a Gleason score (GS) greater than 7 and 54.4 percent of cancers with a GS of 7.
When comparing the combination of ultrasound and MRI-targeted biopsy along with systematic biopsy versus systematic biopsy alone, the study authors found the combination biopsy had a 12.7 percent higher detection of PCa (72.9 percent vs. 60.2 percent) and 11.4 percent higher detection rate for csPCa (62.8 percent vs. 51.4 percent). Targeted biopsy also offered improved detection of PI-RADS 5 (82 percent vs. 76 percent) and PI-RADS 4 lesions (35 percent vs. 28 percent) in comparison to systematic biopsy alone, according to the researchers.
The imaging reveals a focal lesion in the right peripheral zone of the prostate at the mid-gland level in a 60-year-old male study participant. (Images courtesy of Radiology.)
“Although there is still debate regarding the optimal biopsy technique in men without biopsy and with lesions suspicious for cancer at MRI, combined systematic and targeted biopsies for PI-RADS 4 or 5 scores are superior to targeted or systematic biopsies alone in detecting csPCa,” wrote Ghulam Nabi, M.D., a clinical professor in the Division of Imaging Science and Technology at the School of Medicine at the University of Dundee in Dundee, United Kingdom, and colleagues.
Noting challenges with template biopsies and GS grading, the researchers suggested that future research with transcriptomic and radiomic data could enhance a clinician’s understanding of disease grading with intralesional patterns. Nabi and colleagues also emphasized the anterior gland as a potential source of csPCA that was commonly missed in the study.
“The majority of the missed csPCa lesions were smaller than 15 mm and located in the anterior half of the gland,” added Nabi and colleagues. “This observation will be useful for the reporting radiologist to include the anterior gland as a focused review area.”
In regard to study limitations, the researchers noted a lack of interobserver variability among pathologists. They also utilized PI-RADS 2.0 to assess multiparametric MRI findings during the course of the study to help ensure consistency but acknowledged that the updated PI-RADS 2.1 became available in 2019.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).
